BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 9166147)

  • 1. Adjuvant therapy for colon and rectal cancer.
    Ratkin GA
    Am Fam Physician; 1997 May; 55(7):2487-92, 2495-6. PubMed ID: 9166147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group.
    Dahl O; Fluge Ø; Carlsen E; Wiig JN; Myrvold HE; Vonen B; Podhorny N; Bjerkeset O; Eide TJ; Halvorsen TB; Tveit KM;
    Acta Oncol; 2009; 48(3):368-76. PubMed ID: 19242829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III.
    Taal BG; Van Tinteren H; Zoetmulder FA;
    Br J Cancer; 2001 Nov; 85(10):1437-43. PubMed ID: 11720425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early discontinuation but not the timing of adjuvant therapy affects survival of patients with high-risk colorectal cancer: a population-based study.
    Ahmed S; Ahmad I; Zhu T; Arnold FP; Faiz Anan G; Sami A; Yadav SK; Alvi R; Haider K
    Dis Colon Rectum; 2010 Oct; 53(10):1432-8. PubMed ID: 20847626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
    Liersch T; Langer C; Ghadimi BM; Kulle B; Aust DE; Baretton GB; Schwabe W; Häusler P; Becker H; Jakob C
    J Clin Oncol; 2006 Sep; 24(25):4062-8. PubMed ID: 16943523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New approaches to assessing and treating early-stage colon and rectal cancers: cooperative group strategies for assessing optimal approaches in early-stage disease.
    Benson AB
    Clin Cancer Res; 2007 Nov; 13(22 Pt 2):6913s-20s. PubMed ID: 18006800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?
    Gill S; Loprinzi CL; Sargent DJ; Thomé SD; Alberts SR; Haller DG; Benedetti J; Francini G; Shepherd LE; Francois Seitz J; Labianca R; Chen W; Cha SS; Heldebrant MP; Goldberg RM
    J Clin Oncol; 2004 May; 22(10):1797-806. PubMed ID: 15067028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Posttreatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy.
    Chan AK; Wong A; Jenken D; Heine J; Buie D; Johnson D
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):665-77. PubMed ID: 15708244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized controlled trial of postoperative radiotherapy and short-term time-scheduled 5-fluorouracil against surgery alone in the treatment of Dukes B and C rectal cancer. Norwegian Adjuvant Rectal Cancer Project Group.
    Tveit KM; Guldvog I; Hagen S; Trondsen E; Harbitz T; Nygaard K; Nilsen JB; Wist E; Hannisdal E
    Br J Surg; 1997 Aug; 84(8):1130-5. PubMed ID: 9278661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative chemoradiotherapy and total mesorectal excision surgery for locally advanced rectal cancer: correlation with rectal cancer regression grade.
    Wheeler JM; Dodds E; Warren BF; Cunningham C; George BD; Jones AC; Mortensen NJ
    Dis Colon Rectum; 2004 Dec; 47(12):2025-31. PubMed ID: 15657650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deleted in colorectal cancer protein expression as a possible predictor of response to adjuvant chemotherapy in colorectal cancer patients.
    Gal R; Sadikov E; Sulkes J; Klein B; Koren R
    Dis Colon Rectum; 2004 Jul; 47(7):1216-24. PubMed ID: 15148649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set.
    O'Connell MJ; Campbell ME; Goldberg RM; Grothey A; Seitz JF; Benedetti JK; André T; Haller DG; Sargent DJ
    J Clin Oncol; 2008 May; 26(14):2336-41. PubMed ID: 18467725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant therapy in colorectal cancer.
    Parshad R
    Trop Gastroenterol; 1997; 18(4):139-44. PubMed ID: 9612092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Importance of 5-fluorouracil dose-intensity in a double randomised trial on adjuvant portal and systemic chemotherapy for Dukes B2 and C colorectal cancer.
    Focan C; Bury J; Beauduin M; Herman ML; Vindevoghel A; Lecomte M; Brohée D; Canon JL; Focan-Henrard D;
    Anticancer Res; 2000; 20(6C):4665-72. PubMed ID: 11205198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of treatment received versus long-standing guidelines for stage III colon and stage II/III rectal cancer patients diagnosed in Alberta, Saskatchewan, and Manitoba in 2004.
    Cree M; Tonita J; Turner D; Nugent Z; Alvi R; Barss R; King C; Winget M
    Clin Colorectal Cancer; 2009 Jul; 8(3):141-5. PubMed ID: 19632928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrence patterns after curative resection of colorectal cancer in patients followed for a minimum of ten years.
    Sadahiro S; Suzuki T; Ishikawa K; Nakamura T; Tanaka Y; Masuda T; Mukoyama S; Yasuda S; Tajima T; Makuuchi H; Murayama C
    Hepatogastroenterology; 2003; 50(53):1362-6. PubMed ID: 14571738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Adjuvant therapy of rectal cancer].
    Bouaouina N; Boussen H
    Tunis Med; 2003 Feb; 81(2):73-9. PubMed ID: 12708171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors influencing the survival of patients with colon cancer receiving adjuvant 5-FU treatment.
    Kornmann M; Formentini A; Ette C; Henne-Bruns D; Kron M; Sander S; Baumann W; Kreuser ED; Staib L; Link KH
    Eur J Surg Oncol; 2008 Dec; 34(12):1316-21. PubMed ID: 18313881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-institution experience of adjuvant 5-fluorouracil-based chemotherapy for stage III colon cancer.
    Gibbs P; Handolias D; McLaughlin S; Chapman M; Johns J; Faragher I
    Intern Med J; 2008 Apr; 38(4):265-9. PubMed ID: 18298558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.